AG2R LA MONDIALE Adopts Akur8 to Challenge Its Approach to Health Insurance Pricing
29.6.2021 10:00:00 EEST | Business Wire | Press release
AG2R LA MONDIALE and Akur8 are delighted to announce their collaboration to transform AG2R LA MONDIALE's health insurance pricing process. This move underlines AG2R LA MONDIALE's desire to encourage innovation for the benefit of its policyholders. It also reinforces Akur8's relevance in the health insurance sector.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005016/en/
Specifically developed for insurance companies, Akur8's solution enhances their pricing process by automating risk and demand modeling, using a proprietary technology powered by transparent artificial intelligence. Akur8 enables insurers to significantly reduce modeling times, speed up time-to-market and increase predictive power of their models, while retaining absolute transparency and control.
With Akur8, AG2R LA MONDIALE is challenging its health insurance products’ pricing approach in order to offer its policyholders fairer, more transparent and more tailored prices.
"We are delighted to be opening this new chapter with AG2R LA MONDIALE. This move underlines their innovative spirit and ability to adapt constantly in order to serve their clients better, while putting digital transformation at the heart of their plans," said Samuel Falmagne, CEO of Akur8.
"This collaboration with AG2R LA MONDIALE marks a significant step forward in Akur8's continuous development. It reinforces the solution's relevance for health insurance and consolidates our presence in France," said Brune de Linares, Chief of Sales at Akur8.
"We are delighted to collaborate with Akur8. We are constantly seeking to provide better support to our policyholders, in an environment that calls for ever more agility and adaptability. This experimentation with Akur8 is a prime example of this approach. We hope that this unique, intuitive and innovative solution will provide value in the key process of pricing," said Anne-Charlotte de Raigniac, Director of actuarial services and medical approvals at AG2R LA MONDIALE.
About AG2R LA MONDIALE:
As a specialist in social and patrimonial protection in France, AG2R LA MONDIALE insures individuals, businesses and professional branches, providing health protection, protecting assets and income, guarding against accidents and preparing for retirement. The Group has over 15 million policyholders and provides day-to-day support to 500,000 businesses. With more than 11,000 employees, AG2R LA MONDIALE has a presence throughout mainland France and beyond. As a partnership with joint, cooperative governance, the Group cultivates a unique social protection model that closely combines profitability and solidarity, performance and social commitment. Every year it spends millions of euros helping vulnerable people and supporting individual and collaborative initiatives.
Stay up to date: www.ag2rlamondiale.fr / @AG2RLAMONDIALE
About Akur8
Akur8 revolutionizes insurance pricing with transparent AI. Akur8 has developed a unique AI-based insurance pricing solution that automates modeling for insurance companies while keeping full transparency and control over the models created, as required by regulators worldwide. Akur8 is the only solution on the market that reconciles the Machine Learning and Actuarial worlds.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005016/en/
Contact information
Press Contacts
For Akur8
Anne-Laure Klein
+33 (0)6 63 79 44 74
anne-laure.klein@akur8-tech.com
For AG2R LA MONDIALE
Mélissa Bourguignon
+33 (0)6 04 52 18 63
melissa.bourguignon@ag2rlamondiale.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom